Glaukos Corp (FRA:6GJ)
€ 153 (0%) Market Cap: 9.21 Bil Enterprise Value: 9.05 Bil PE Ratio: 0 PB Ratio: 15.69 GF Score: 79/100

Glaukos Corp at JPMorgan Healthcare Conference Transcript

Jan 14, 2026 / 12:30AM GMT
Release Date Price: €82 (-12.77%)
Allen Gong
JPMorgan Chase & Co - Analyst

Okay. Thanks, everyone, for joining us today. My name is Allen Gong here on the medical supplies and devices team at JPMorgan. Really glad to be introducing the management team at Glaukos today. We're going to start off with some prepared remarks from CEO, John Burns, and then we'll tag in Alex and Joe for some Q&A afterwards.

Thomas Burns
Glaukos Corp - Chairman of the Board, Chief Executive Officer

Okay. Thanks, Al. Well, good afternoon, and thank you, everyone, for coming today. I do want to formally introduce Joe Gilliam, who's our President and Chief Operating Officer; Alex Thurman, who's our Chief Financial Officer; and we have Chris Lewis in the back, who's our VP of Investor Relations. So I'm happy and delighted to give you an update on the progress we're making in the business.

Begin talking about what we're about. Innovation is at the core of everything we do in the company. I think that innovation has propelled us into a company that's been the maker of new markets in ophthalmology. If you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot